The sale is small and routine for a director exercising options. Monitor for any additional insider selling patterns in future filings, but this single filing carries no material signal.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Oct 29 $13.65entry
- T+1 · 7d ago −4.03%α −3.55% · $13.10
- T+5 · due 13h ago Pending
- T+5 · todayOpen
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Director Dennis Podlesak filed a Form 144 notice of intent to sell 8,000 shares of Syndax Pharmaceuticals common stock, with an estimated aggregate market value of $114,560. The shares were acquired through exercise of stock options on the same date as the filing. The sale is small relative to the company's $1.2B market cap and represents a routine insider transaction.
Key Facts
- Director Dennis Podlesak filed Form 144 to sell 8,000 shares
- Estimated aggregate market value of $114,560
- Shares acquired via exercise of stock options on 10/29/2026
- Sale intended on Nasdaq exchange
- Filing date: 2026-10-29
Financial Impact
8,000 shares at ~$14.32 per share, representing less than 0.01% of market cap
Risk Factors
- Form 144 is only an intent to sell; the transaction may not be executed
- Insider selling ahead of potential catalysts could be a concern if it becomes a pattern
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-010480 |
| Document: 0001950047-26-010480-index.html | 0001950047-26-010480 |
| Document: 0001950047-26-010480.txt | 0001950047-26-010480 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Nov 2, 2026 3d ago | 8-K | No price | awaiting T+60 | awaiting T+60 | No price |
Nov 2, 2026 3d ago | Press Release | No price | awaiting T+60 | awaiting T+60 | No price |
Nov 2, 2026 3d ago | Press Release | $14.29 | awaiting T+60 | awaiting T+60 | $9.37 (−34.43%) |
Oct 29, 2026 7d ago | 144 | $13.65 | awaiting T+60 | awaiting T+60 | $9.37 (−31.36%) |
Jul 14, 2026 16w ago | 8-K | $24.13 $17.03 | ▼ −29.42% | ▼ −32.80% | $9.37 (−61.17%) |
Jul 1, 2026 18w ago | Press Release | $21.82 $18.20 | ▼ −16.59% | ▼ −20.16% | $9.37 (−57.06%) |
Jun 11, 2026 21w ago | Press Release | $17.91 $20.56 | ▲ +14.80% | ▲ +10.40% | $9.37 (−47.68%) |
Jun 10, 2026 21w ago | 8-K | $17.91 $20.56 | ▲ +14.80% | ▲ +10.40% | $9.37 (−47.68%) |
Jun 4, 2026 22w ago | Press Release | $17.34 $19.29 | ▲ +11.25% | ▲ +7.25% | $9.37 (−45.96%) |
Jun 4, 2026 22w ago | DEFA14A | $18.02 $19.54 | ▲ +8.44% | ▲ +6.55% | $9.37 (−48.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers